Boris Pasche, President and CEO at Karmanos Cancer Institute, Co-founder and Member at TheraBionic, shared a post on LinkedIn:
“TheraBionic is present at GI ASCO, booth 114.
The TheraBionic P1 device is FDA-approved for patients with advanced hepatocellular carcinoma who have failed first-line and second-line therapies. This device represents the first systemic targeted therapy for cancer and is available throughout the United States. This transformative treatment can be used in patients with severely impaired function.”
More posts about ASCOGI26.